bmi for semaglutide Most viewed this week from JAMA Internal Medicine: 50 mg of oral # daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or # Long-term weight loss effects of

Personalized Support for Sustainable Weight Loss.

It is given as an injection under the skin (subcutaneously), every 2 weeks or once a month

In the ACHIEVE-1 phase 3 trial, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes

In addition, perioperative management of patients on GLP-1 RAs requires careful assessment as a result of delayed gastric emptying and the associated potential risk of pulmonary aspiration

It is no secret that GLP-1 receptor agonists have transformed the treatment of obesity and diabetes

Beyond these frontrunners, the pipeline is expanding: Novo Nordisk filed for FDA approval of CagriSema in 2025, the first once-weekly combination of GLP1 and amylin analogue